BioSpace News Archive

The Company expects to report the financial results for the fourth quarter and full year of 2017 after 5:00 PM ET on Tuesday, February 27, 2018.

To participate on the live call, please dial 866-550-8145 (domestic) or +1-430-775-1344 (international) and provide the conference ID 7796295 five to 10 minutes before the start of the call.

All of the shares in the offering will be sold by Affimed.

Results from randomized phase II CONDOR trial suggest the immune checkpoint blocker is safe and shows encouraging anti-tumor activity as second-line treatment in tumors with low/negative PD-L1; no difference in clinical activity observed between durvalumab alone or in combination with tremelimumab [13-February-2018] SCOTTSDALE, Ariz., Feb. 13, 2018 /PRNewswir

Results of the phase II OPTIMA clinical trial indicate that patients with head and neck cancers associated with the HPV, including those with advanced nodal disease, can receive substantially lower radiation doses safely and effectively if they respond to induction chemotherapy initially.

On 15 August 2017, Ossur initiated a share buy-back program.

The Kendall Square facility will support robust customer growth and connect Alcami to the forefront of hundreds of thriving pharma and biotech start-ups and innovators.

This information will be available on the Company’s website www.kewaunee.com after the release.

Ra Pharma today announced that it intends to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering.

As COO, Ms. Lind is responsible for the Company’s manufacturing, engineering, quality and IT departments.